Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Pharmacological treatment of depression in people with a primary brain tumour

The issue

People with brain tumours may experience epilepsy, memory problems, and fatigue. Depression is also common, and doctors might choose to treat this with antidepressants, since antidepressants are thought to be effective in other patients. However, antidepressants could be less effective, or could cause more side effects, in people with a primary brain tumour.

The aim of the review

We researched whether any drugs have been proven to be effective, and whether they cause significant side effects when prescribed to treat depression in people with primary brain tumours.

Main findings

We searched the medical journal literature to find high-quality studies comparing the effectiveness of any one drug treatment for depression in people with a brain tumour against another treatment. Despite a thorough search, we could not find any studies and so cannot determine whether any drug is of benefit.

What are the conclusions?

We conclude that it is important to research whether drugs can treat depression safely and effectively in people with primary brain tumours.

Quality of evidence

No studies were eligible for this review.

Wprowadzenie

This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013.

People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear.

Cele

To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour.

Metody wyszukiwania badań

We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019).

Kryteria doboru badań

We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour.

Zbieranie i analiza danych

No studies met the inclusion criteria.

Główne wyniki

We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour.

Wnioski autorów

We identified no high-quality studies that investigated the value of pharmacological treatment of depression in people with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional information to change these conclusions.

Cytowanie
Beevers Z, Hussain S, Boele FW, Rooney AG. Pharmacological treatment of depression in people with a primary brain tumour. Cochrane Database of Systematic Reviews 2020, Issue 7. Art. No.: CD006932. DOI: 10.1002/14651858.CD006932.pub4.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj